Author: | Maki, R. G. |
Article Title: | Recent advances in therapy for gastrointestinal stromal tumors |
Abstract: | Sarcomas comprise less than 1% of all cancers. Gastrointestinal stromal tumor (GIST) is the most common form of sarcoma and can vary in size and clinical outcome from an incidental finding at operation to life-threatening metastatic disease. Surgery is the standard of care for primary disease, and the oral drug imatinib is the standard of care for metastatic disease. Sunitinib was approved in the United States in early 2006 for GIST that is refractory to imatinib. The pathology of GIST, surgical options for primary and metastatic disease, and findings leading to the use of imatinib and sunitinib for GIST are highlighted in this review. Copyright © 2007 by Current Medicine Group LLC. |
Keywords: | gene mutation; clinical feature; clinical trial; histopathology; review; placebo; sunitinib; cancer risk; drug withdrawal; unspecified side effect; antineoplastic agents; drug approval; united states; combined modality therapy; gastrointestinal stromal tumor; imatinib; stem cell factor receptor; gene overexpression; interstitial cell of cajal; gastrointestinal stromal tumors; enzyme inhibition; platelet derived growth factor receptor; pyrimidines; cancer therapy; risk assessment; sarcoma; protein kinase inhibitors; standardization; cancer size; neoplasm metastasis; outcomes research; protein-tyrosine kinases; metastasis potential; gastrointestinal surgery; piperazines; incidental finding; indoles; pyrroles; angiogenesis inhibitors; drug sensitivity; phosphotransferase; everolimus; drug indication |
Journal Title: | Current Oncology Reports |
Volume: | 9 |
Issue: | 3 |
ISSN: | 1523-3790 |
Publisher: | Springer |
Date Published: | 2007-05-01 |
Start Page: | 165 |
End Page: | 169 |
Language: | English |
DOI: | 10.1007/s11912-007-0017-0 |
PUBMED: | 17430686 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 9" - "Export Date: 17 November 2011" - "CODEN: CORUA" - "Source: Scopus" |